We are in the process of full molecular characterization of the primary human xenograft samples used in this study, but given the preponderance of Ink4a mutations in primary human pancreatic cancers [41], we believe that a similar conclusion is likely for our primary human xenograft samples. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.